BIOMAT Database Logo BIOMAT Database Logo

Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil. 1993

S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Department of Clinical Pharmacology, University Hospital, Frankfurt/Main, Fed. Rep. of Germany.

The results of enantioselective analysis of verapamil (CAS 52-53-9) in plasma samples obtained at tmax after single dose applications of a 80 mg fast dissoluting (IR) tablet, a controlled release (CR) formulation (240 mg) and an intravenous injection of 5 mg verapamil are reported. The mean fraction of S-verapamil obtained in samples containing the Cmax of racemic verapamil was somewhat smaller after application of the IR-form than observed with the CR formulation. (IR = 15.8 +/- 3.8%; CR = 18.8 +/- 2.0%; p < 0.01), after the intravenous application the mean S-fraction was 32.8 +/- 1.4%. In vitro dissolution tests of the two oral preparations prove that the isomers were released as racemate.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations.
August 1987, Arzneimittel-Forschung,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Bioavailability study of two different verapamil formulations.
August 1992, Archiv der Pharmazie,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Plasma concentrations after three different doses of topical isotretinoin.
January 1994, Skin pharmacology : the official journal of the Skin Pharmacology Society,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Plasma tenoxicam concentrations after single and multiple oral doses.
January 1989, European journal of drug metabolism and pharmacokinetics,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses.
June 1991, The Journal of tropical medicine and hygiene,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Bioequivalence assessment of two different tablet formulations of diltiazem after single and repeated doses in healthy subjects.
January 1999, Current medical research and opinion,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Plasma and salivary concentrations of erythromycin after administration of three different formulations.
October 1980, Postgraduate medical journal,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction.
June 2000, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Plasma concentrations of trifluoperazine following single low doses.
August 1983, Canadian Medical Association journal,
S Harder, and M Siewert, and P Thürmann, and H Blume, and N Rietbrock, and B Siewert
Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste.
June 1996, Journal of clinical pharmacology,
Copied contents to your clipboard!